Quarterly ResultMay 7, 2026, 04:33 PM
Absci Reports Q1 2026 Results; ABS-201 Trial Progresses, Adds ABS-202
AI Summary
Absci Corporation reported its first-quarter 2026 financial results, including a net loss of $29.6 million and revenue of $0.2 million. The company also provided significant business updates, announcing successful dosing of all four healthy volunteer SAD cohorts for its ABS-201 HEADLINE trial, with favorable safety data and preliminary PK modeling supporting a targeted dosing interval. Additionally, Absci initiated dosing for the first MAD cohort of AGA participants and expanded its internal pipeline with ABS-202 for an undisclosed inflammation and immunology indication. The company projects its cash and equivalents will fund operations into the first half of 2028.
Key Highlights
- Successfully dosed all four healthy volunteer SAD cohorts of ABS-201 HEADLINE trial.
- Initiated dosing of first MAD cohort of AGA participants for ABS-201.
- Expanded internal pipeline with ABS-202 for an undisclosed I&I indication.
- Q1 2026 revenue was $0.2 million, down from $1.2 million in Q1 2025.
- Net loss for Q1 2026 was $29.6 million, compared to $26.3 million in Q1 2025.
- R&D expenses increased to $19.3 million from $16.4 million YoY.
- Cash, cash equivalents, and marketable securities totaled $125.7 million as of March 31, 2026.
- Cash runway projected into the first half of 2028.